Ftse Mib
33.280,87
0,16%
DAX
19.146,17
0,76%
S&P 500
5.962,39
0,77%
NASDAQ
18.991,14
0,13%
Bitcoin
98.409,04
4,29%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aurinia Pharmaceuticals Inc (AUPH) Aurinia Pharmaceuticals Inc (AUPH) Notizie

Aurinia Pharmaceuticals Inc

AUPH
8,70
0,46 (5,58%)
Ultimo aggiornamento: 20:59:14
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/11/202423:53BWAurinia Commends 2024 Updated ACR Guidelines for Screening,..
15/11/202412:00BWAurinia Presents New Data Underscoring Critical Importance..
14/11/202422:47EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202412:00BWAurinia to Participate in Jefferies London Healthcare..
13/11/202401:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202401:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/11/202412:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202412:13EDGAR2Form 8-K - Current report
07/11/202412:10BWAurinia Pharmaceuticals Appoints Craig Johnson to Board of..
07/11/202412:00BWAurinia Pharmaceuticals Reports Third Quarter and Nine..
30/10/202421:05BWAurinia Pharmaceuticals to Release Third Quarter Financial..
11/10/202412:00BWAurinia Presents New Data Highlighting Real-World..
24/9/202414:10BWAurinia Announces Japan Approval of LUPKYNIS® (Voclosporin)..
20/9/202422:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/9/202412:00BWAurinia to Participate in 2024 Cantor Fitzgerald Global..
12/9/202422:08EDGAR2Form 8-K - Current report
12/9/202422:05BWAurinia Announces Board Restructuring
05/9/202412:00BWAurinia Announces First Participant Dosed in AUR200 Single..
28/8/202412:00BWAurinia to Participate in H.C. Wainwright 26th Annual Global..
08/8/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202412:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202412:03EDGAR2Form 8-K - Current report
01/8/202412:00BWAurinia Pharmaceuticals Reports Second Quarter and Six..
19/7/202412:00BWAurinia Pharmaceuticals to Release Second Quarter Financial..
02/7/202412:00BWAurinia to Participate in Upcoming Investor Healthcare..
14/6/202423:25EDGAR2Form 8-K - Current report
14/6/202418:16BWAurinia Announces 2024 Annual General Meeting Results
05/6/202412:00BWAurinia Presents Safety and Efficacy Profile of LUPKYNIS®..
04/6/202423:30BWAurinia Addresses Dubious Proposals Put Forth by Lucien..
04/6/202423:25EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/6/202400:30BWAurinia Provides Update on Proxy Statement
30/5/202412:00BWAurinia Will Attend 2024 Jefferies Global Healthcare..
22/5/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202412:00BWAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for..
09/5/202412:00BWAurinia Presents Data Reinforcing LUPKYNIS® Safety and..
07/5/202412:00BWAurinia Will Attend 2024 RBC Capital Markets Global..
02/5/202412:00BWAurinia Pharmaceuticals Reports First Quarter 2024 Financial..
01/5/202412:00BWAurinia Underscores Enduring Commitment to People Living..
30/4/202412:00BWThe U.S. Food & Drug Administration (FDA) Approves Updated..
16/4/202416:48BWUPDATE: New Aurinia Presentation Details at the 2024 Bloom..
15/4/202412:00BWAurinia Pharmaceuticals to Release First Quarter Financial..
09/4/202412:00BWAurinia Will Attend 2024 Bloom Burton & Co. Healthcare..
07/3/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 8,311 Min: 8,30 Max: 8,7299
Chiusura: 8,24

La tua Cronologia

NASDAQ
AUPH
Aurinia Pharmaceuticals
LSE
WNWD
Windward
AQSE
LEND.GB
Sancus Lending
NASDAQ
FAXPX
Agf American Growth Fund...
COIN
AREUR
Arweave
BIT
RWAY
Rai Way S.p.A
NASDAQ
FNBND
USOTC
RSMES
Rse Archive (GM)
USOTC
LSRCF
Lasertec (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network